- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03177850
Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude
Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease at Altitude, Assessed by Respiratory Polygraphy: A Randomized, Placebo-controlled, Double-blind Parallel Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of acetazolamide (375 mg per day) vs. placebo on sleep related breathing disturbances in lowlanders with chronic obstructive pulmonary disease travelling to altitude. Participants living in the Bishkek area, Kyrgyzstan (760m), will be transferred by car within 4h to the Tuja Ashu high altitude clinic (3200 m), and stay there for 2 days. Acetazolamide 375mg/day (or placebo), will be administered 24 hours before departure at 760 m and during the stay at altitude. Outcomes will be assessed during the stay at 3200 m.
Sleep related breathing disturbances will be evaluated by respiratory polygraphy.
An interim analysis will be carried out when 90 patients will have completed the study or after the first year. The Peto's method will be used to correct the P-values.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bishkek, Kyrgyzstan, 720040
- National Center of Cardiology and Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients, age 18-75 yrs.
- COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92% at 750 m.
- Born, raised and currently living at low altitude (<800m).
- Written informed consent.
Exclusion Criteria:
- COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7, FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).
- Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.
- Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (>20 cigarettes per day)
- Known renal failure or allergy to acetazolamide and other sulfonamides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ACETAZOLAMIDE oral capsule
Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally.
Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
|
Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
|
Placebo Comparator: PLACEBO oral capsule
Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally.
Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
|
Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in nocturnal oxygen saturation
Time Frame: night 1 at 760m and night 1 at 3200 m
|
Difference in altitude-induced change in mean nocturnal oxygen saturation measured by pulse oximetry between acetazolamide and placebo group
|
night 1 at 760m and night 1 at 3200 m
|
Change in nocturnal oxygen desaturation index
Time Frame: night 1 at 760m and night 1 at 3200 m
|
Difference in altitude-induced change in the mean number of cyclic dips in oxygen saturation measured by pulse oximetry between acetazolamide and placebo group
|
night 1 at 760m and night 1 at 3200 m
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in nocturnal oxygen saturation
Time Frame: night 1 at 760m and night 2 at 3200 m
|
Difference in altitude-induced change in mean nocturnal oxygen saturation measured by pulse oximetry between acetazolamide and placebo group
|
night 1 at 760m and night 2 at 3200 m
|
Change in nocturnal oxygen desaturation index
Time Frame: night 1 at 760m and night 2 at 3200 m
|
Difference in altitude-induced change in the mean number of cyclic dips in oxygen saturation measured by pulse oximetry between acetazolamide and placebo group
|
night 1 at 760m and night 2 at 3200 m
|
Change in apnea/hypopnea index
Time Frame: night 1 at 760m and night 1 at 3200 m
|
Difference in altitude-induced change in mean number of apneas/hypopneas per hour between the acetazolamide and placebo group
|
night 1 at 760m and night 1 at 3200 m
|
Change in apnea/hypopnea index
Time Frame: night 1 at 760m and night 2 at 3200 m
|
Difference in altitude-induced change in mean number of apneas/hypopneas per hour between the acetazolamide and placebo group
|
night 1 at 760m and night 2 at 3200 m
|
Change in subjective sleepiness and sleep quality
Time Frame: Day 1 and 2 at 760m and 3200m
|
Difference in altitude-induced change in subjective sleepiness and sleep quality assessed by a visual analog scale between acetazolamide and placebo group
|
Day 1 and 2 at 760m and 3200m
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-00137D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on ACETAZOLAMIDE oral capsule
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedAcute Mountain SicknessKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary DiseaseKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...Active, not recruitingAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary Disease (COPD)Kyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...Active, not recruitingAltitude HypoxiaKyrgyzstan
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary DiseaseKyrgyzstan